Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Marizomib||NPI-0052||Marizomib (NPI-0052) is an irreversible inhibitor of the 20S proteasome, which leads to cell cycle arrest and apoptosis in tumor cells (PMID: 16891470).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||multiple myeloma||not applicable||Marizomib||Phase I||Actionable||In a Phase I trial, Marizomib (NPI-0052) treatment resulted in objective response in 14.8% (4/27) and stable disease in 44.4% (12/27) of patients with relapsed and/or refractory multiple myeloma (PMID: 27117181).||27117181|
|Unknown unknown||lymphoma||not applicable||Marizomib||Phase I||Actionable||In a Phase I trial, Marizomib (NPI-0052) treatment resulted in complete response lasting more than 10 treatment cycles in 7.1% (1/14) of lymphoma patients (PMID: 27117181).||27117181|
|Unknown unknown||Advanced Solid Tumor||not applicable||Marizomib||Phase I||Actionable||In a Phase I trial, Marizomib (NPI-0052) treatment resulted in stable disease of short duration in 29% (7/24) of patients with advanced solid tumors (PMID: 27117181).||27117181|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04341311||Phase I||Marizomib + Panobinostat Marizomib||Phase I Study of Marizomib + Panobinostat for Children With DIPG (DIPG)||Not yet recruiting|
|NCT03727841||Phase II||Marizomib||Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma||Recruiting|